Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial
Deborah Cromer, Arnold Reynaldi, Megan Steain, James A. Triccas, Miles P. Davenport, David S. Khoury
Abstract
The vaccine candidate CVnCoV (CUREVAC) showed surprisingly low efficacy in a recent phase 3 trial compared with other messenger RNA (mRNA) vaccines. Here we show that the low efficacy follows from the dose used and the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and is predicted by the neutralizing antibody response induced by the vaccine.
Topics & Concepts
MedicineNeutralizationNeutralizing antibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)In vitroMessenger RNAAntibodyAntibody responseVirologyCoronavirus2019-20 coronavirus outbreakImmunologyClinical trialInternal medicineGeneOutbreakBiologyDiseaseBiochemistryInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesViral gastroenteritis research and epidemiology